RU2699285C2 - Одноцепочечные белки-агонисты trail-рецептора - Google Patents

Одноцепочечные белки-агонисты trail-рецептора Download PDF

Info

Publication number
RU2699285C2
RU2699285C2 RU2016145608A RU2016145608A RU2699285C2 RU 2699285 C2 RU2699285 C2 RU 2699285C2 RU 2016145608 A RU2016145608 A RU 2016145608A RU 2016145608 A RU2016145608 A RU 2016145608A RU 2699285 C2 RU2699285 C2 RU 2699285C2
Authority
RU
Russia
Prior art keywords
trail
seq
cell
receptor agonist
domain
Prior art date
Application number
RU2016145608A
Other languages
English (en)
Russian (ru)
Other versions
RU2016145608A3 (cg-RX-API-DMAC7.html
RU2016145608A (ru
Inventor
Оливер ХИЛЛ
Кристиан ГИФФЕРС
Майнольф Тиманн
Фриц Г. БЬЮКАНАН
Даррен К. ФИЛЛИПС
Сьюзан Э. ЛЭПП
Original Assignee
Эббви Инк.
Апогеникс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Инк., Апогеникс Аг filed Critical Эббви Инк.
Publication of RU2016145608A publication Critical patent/RU2016145608A/ru
Publication of RU2016145608A3 publication Critical patent/RU2016145608A3/ru
Application granted granted Critical
Publication of RU2699285C2 publication Critical patent/RU2699285C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
RU2016145608A 2014-04-23 2015-04-23 Одноцепочечные белки-агонисты trail-рецептора RU2699285C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
US61/983,152 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (3)

Publication Number Publication Date
RU2016145608A RU2016145608A (ru) 2018-05-28
RU2016145608A3 RU2016145608A3 (cg-RX-API-DMAC7.html) 2018-12-26
RU2699285C2 true RU2699285C2 (ru) 2019-09-04

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016145608A RU2699285C2 (ru) 2014-04-23 2015-04-23 Одноцепочечные белки-агонисты trail-рецептора

Country Status (38)

Country Link
US (5) US9908927B2 (cg-RX-API-DMAC7.html)
EP (2) EP3134430B1 (cg-RX-API-DMAC7.html)
JP (2) JP6523331B2 (cg-RX-API-DMAC7.html)
KR (2) KR102079919B1 (cg-RX-API-DMAC7.html)
CN (2) CN106459221B (cg-RX-API-DMAC7.html)
AR (1) AR100168A1 (cg-RX-API-DMAC7.html)
AU (3) AU2015249649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016024515B1 (cg-RX-API-DMAC7.html)
CA (2) CA3184067A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002683A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160516A (cg-RX-API-DMAC7.html)
CY (1) CY1120281T1 (cg-RX-API-DMAC7.html)
DK (1) DK3134430T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000284A (cg-RX-API-DMAC7.html)
EC (1) ECSP16089579A (cg-RX-API-DMAC7.html)
ES (1) ES2672368T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180950T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038914T2 (cg-RX-API-DMAC7.html)
IL (2) IL248244B (cg-RX-API-DMAC7.html)
LT (1) LT3134430T (cg-RX-API-DMAC7.html)
MA (2) MA45069A (cg-RX-API-DMAC7.html)
MX (2) MX2016013858A (cg-RX-API-DMAC7.html)
MY (1) MY181986A (cg-RX-API-DMAC7.html)
NO (1) NO2776305T3 (cg-RX-API-DMAC7.html)
PE (1) PE20170299A1 (cg-RX-API-DMAC7.html)
PH (2) PH12020500377A1 (cg-RX-API-DMAC7.html)
PL (1) PL3134430T3 (cg-RX-API-DMAC7.html)
PT (1) PT3134430T (cg-RX-API-DMAC7.html)
RS (1) RS57153B1 (cg-RX-API-DMAC7.html)
RU (1) RU2699285C2 (cg-RX-API-DMAC7.html)
SG (3) SG11201608767XA (cg-RX-API-DMAC7.html)
SI (1) SI3134430T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800286T1 (cg-RX-API-DMAC7.html)
TR (1) TR201806912T4 (cg-RX-API-DMAC7.html)
TW (2) TWI747178B (cg-RX-API-DMAC7.html)
UA (1) UA118286C2 (cg-RX-API-DMAC7.html)
UY (1) UY36095A (cg-RX-API-DMAC7.html)
WO (1) WO2015164588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
CA3002602C (en) 2015-10-23 2021-11-02 Apogenix Ag Single-chain cd27-receptor agonist proteins
CA3002587A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
CN108473549A (zh) * 2015-10-23 2018-08-31 阿珀吉科吉尼科斯股份公司 单链gitr受体激动剂蛋白
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7091248B2 (ja) 2016-03-01 2022-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質
KR20180127407A (ko) * 2016-03-16 2018-11-28 메리맥 파마슈티컬즈, 인크. 암 요법용 조작된 trail
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017283487A1 (en) * 2016-06-13 2018-11-22 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2019032952A1 (en) * 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
CN115836084A (zh) 2020-05-15 2023-03-21 阿珀吉尼科斯股份公司 多特异性免疫调节剂
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
RU2429006C2 (ru) * 2005-02-18 2011-09-20 Дженентек, Инк. Комбинация apo2l/trail и ингибитора egfr для лечения рака, способ in vitro усиления апоптоза и применение комбинации для получения лекарственного средства для лечения рака
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
ATE406384T1 (de) 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US8388962B2 (en) 2005-04-15 2013-03-05 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating MCP-1/CCR2 associated diseases
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
ES2560871T3 (es) 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2737280A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
EP2379585A2 (en) * 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
AU2011240620A1 (en) 2010-04-13 2012-10-18 Medimmune, Llc Fibronectin type III domain-based multimeric scaffolds
CA2878992C (en) 2012-07-18 2020-09-22 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429006C2 (ru) * 2005-02-18 2011-09-20 Дженентек, Инк. Комбинация apo2l/trail и ингибитора egfr для лечения рака, способ in vitro усиления апоптоза и применение комбинации для получения лекарственного средства для лечения рака
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUMMINS N. ET AL., The TRAIL to viral pathogenesis: the good, the bad and the ugly, Curr. Mol. Med., 2009, v.9, n.4, p.495-505. *
GIEFFERS C. ET AL., APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors, MOLECULAR CANCER THERAPEUTICS, 2013, v.12, n.12, p.2735-2747. *

Also Published As

Publication number Publication date
AR100168A1 (es) 2016-09-14
RS57153B1 (sr) 2018-07-31
JP2017513503A (ja) 2017-06-01
PL3134430T3 (pl) 2018-08-31
RU2016145608A3 (cg-RX-API-DMAC7.html) 2018-12-26
CA2946402C (en) 2023-02-28
CA2946402A1 (en) 2015-10-29
IL272612A (en) 2020-03-31
US20240174731A1 (en) 2024-05-30
MA39770A (fr) 2015-10-29
EP3366699A1 (en) 2018-08-29
US20250145688A1 (en) 2025-05-08
EP3134430A1 (en) 2017-03-01
IL248244B (en) 2020-03-31
RU2016145608A (ru) 2018-05-28
JP2019162114A (ja) 2019-09-26
SG10202111785VA (en) 2021-12-30
CN106459221B (zh) 2020-09-01
TWI747178B (zh) 2021-11-21
PE20170299A1 (es) 2017-05-06
PH12016502079A1 (en) 2016-12-19
MX2016013858A (es) 2017-08-02
ES2672368T3 (es) 2018-06-14
LT3134430T (lt) 2018-05-10
SMT201800286T1 (it) 2018-07-17
KR20190135546A (ko) 2019-12-06
JP6523331B2 (ja) 2019-05-29
MX2019013587A (es) 2020-01-13
CA3184067A1 (en) 2015-10-29
MY181986A (en) 2021-01-18
BR112016024515B1 (pt) 2020-03-31
PH12020500377A1 (en) 2022-11-14
US20180222962A1 (en) 2018-08-09
SG10201806465TA (en) 2018-08-30
AU2015249649A1 (en) 2016-11-10
AU2020202247A1 (en) 2020-04-23
TW202024123A (zh) 2020-07-01
UY36095A (es) 2015-10-30
BR112016024515A2 (pt) 2017-10-10
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
AU2015249649B2 (en) 2018-10-04
TR201806912T4 (tr) 2018-06-21
KR20170012257A (ko) 2017-02-02
US20150337027A1 (en) 2015-11-26
HUE038914T2 (hu) 2018-12-28
EP3134430B1 (en) 2018-03-21
TWI683825B (zh) 2020-02-01
NO2776305T3 (cg-RX-API-DMAC7.html) 2018-01-27
NZ725476A (en) 2023-09-29
CR20160516A (es) 2017-05-10
KR102079919B1 (ko) 2020-02-24
SG11201608767XA (en) 2016-11-29
US9908927B2 (en) 2018-03-06
JP6714751B2 (ja) 2020-06-24
UA118286C2 (uk) 2018-12-26
SI3134430T1 (en) 2018-05-31
CL2016002683A1 (es) 2017-07-07
TW201620928A (zh) 2016-06-16
ECSP16089579A (es) 2018-05-31
HRP20180950T1 (hr) 2018-08-10
CY1120281T1 (el) 2019-07-10
WO2015164588A1 (en) 2015-10-29
PH12016502079B1 (en) 2016-12-19
AU2018271369A1 (en) 2018-12-20
DOP2016000284A (es) 2017-02-15
DK3134430T3 (en) 2018-05-22
PT3134430T (pt) 2018-04-20
CN106459221A (zh) 2017-02-22
US20210040178A1 (en) 2021-02-11
MA45069A (fr) 2019-04-03
IL248244A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
RU2699285C2 (ru) Одноцепочечные белки-агонисты trail-рецептора
ES2754432T3 (es) Proteínas agonistas de receptor CD40 de cadena sencilla
AU2016341400A1 (en) Single-chain CD137-receptor agonist proteins
JP2018533948A (ja) 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
AU2016341402B2 (en) Single-chain GITR-receptor agonist proteins
US20180230196A1 (en) Single-chain ox40-receptor agonist proteins
HK1260151A1 (en) Single-chain trail-receptor agonist proteins
HK1235072B (en) Single-chain trail-receptor agonist proteins
HK1235072A1 (en) Single-chain trail-receptor agonist proteins
NZ725476B2 (en) Single-chain trail-receptor agonist proteins